Gambaran Umum
Renovaro Inc. (RENB) is a U.S.-based biotechnology company focused on developing advanced immunotherapy solutions for the treatment of cancer and infectious diseases. The company specializes in innovative cell and gene therapy technologies aimed at enhancing the body’s immune response to fight diseases more effectively. Renovaro is engaged in clinical research and development, working to bring next-generation treatments to the healthcare market.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Lunai Bioworks Inc. per 2025 Mar 31 adalah -19.90 MM.
- Nilai net income untuk Lunai Bioworks Inc. per 2025 Mar 31 adalah -59.23 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-03-31 | -19.90 | -59.23 | |
2024-12-31 | -24.50 | -118.41 | |
2024-09-30 | -24.23 | -115.69 | |
2024-06-30 | -27.39 | -80.65 | |
2024-03-31 | -25.90 | -95.89 | |
2023-12-31 | -21.19 | -41.23 | |
2023-09-30 | -21.29 | -41.16 | |
2023-06-30 | -19.60 | -39.68 | |
2023-03-31 | -20.58 | -106.72 | |
2022-12-31 | -20.55 | -108.60 | |
2022-09-30 | -22.51 | -110.72 | |
2022-06-30 | -22.83 | -113.43 | |
2022-03-31 | -32.05 | -40.56 | |
2021-12-31 | -31.07 | -38.39 | |
2021-09-30 | -28.05 | -34.74 | |
2021-06-30 | -23.40 | -26.72 | |
2021-03-31 | -12.05 | -13.46 | |
2020-12-31 | -12.83 | -10.94 | |
2020-09-30 | -12.34 | -9.73 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah -0.38.
- laba per saham yang terdilusi untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah -0.38.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-03-31 | -0.38 | -0.38 |
2024-12-31 | -0.82 | -0.82 |
2024-09-30 | -0.97 | -0.97 |
2024-06-30 | -0.84 | |
2024-03-31 | -1.29 | -1.29 |
2023-12-31 | -0.67 | -0.67 |
2023-09-30 | -0.70 | -0.70 |
2023-06-30 | -0.71 | |
2023-03-31 | -1.94 | -1.94 |
2022-12-31 | -2.01 | -2.01 |
2022-09-30 | -2.08 | -2.08 |
2022-06-30 | -2.16 | |
2022-03-31 | -0.79 | -0.79 |
2021-12-31 | -0.77 | -0.77 |
2021-09-30 | -0.72 | -0.72 |
2021-06-30 | -0.57 | |
2021-03-31 | -0.29 | -0.29 |
2020-12-31 | -0.24 | -0.24 |
2020-09-30 | -0.21 | -0.21 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Lunai Bioworks Inc. per 2025 Mar 31 adalah -8.48 MM.
- Nilai cash from investing activities untuk Lunai Bioworks Inc. per 2025 Mar 31 adalah -1.52 MM.
- Nilai kas dari aktivitas pendanaan untuk Lunai Bioworks Inc. per 2025 Mar 31 adalah 10.67 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-03-31 | -8.48 | -1.52 | 10.67 |
2024-12-31 | -9.62 | -0.14 | 9.73 |
2024-09-30 | -10.21 | -0.20 | 9.98 |
2024-06-30 | -10.97 | -1.26 | 10.52 |
2024-03-31 | -10.82 | -1.21 | 9.30 |
2023-12-31 | -11.49 | -1.12 | 8.77 |
2023-09-30 | -11.90 | -1.09 | 5.62 |
2023-06-30 | -11.77 | -0.03 | 4.52 |
2023-03-31 | -12.56 | -0.02 | 4.34 |
2022-12-31 | -12.04 | -0.02 | 2.46 |
2022-09-30 | -13.11 | 0.00 | 5.71 |
2022-06-30 | -15.73 | -0.01 | 4.25 |
2022-03-31 | -25.71 | -0.04 | 32.38 |
2021-12-31 | -25.26 | -0.04 | 35.59 |
2021-09-30 | -23.13 | -0.05 | 32.60 |
2021-06-30 | -20.61 | -0.05 | 32.60 |
2021-03-31 | -9.83 | -0.02 | 3.40 |
2020-12-31 | -11.34 | -0.06 | 6.16 |
2020-09-30 | -11.41 | -0.12 | 6.20 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah 1.12.
- p/tbv untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah -3.54.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-03-31 | 1.12 | -3.54 | |
2024-12-31 | 1.41 | -6.87 | |
2024-09-30 | -1.35 | 0.43 | -1.79 |
2024-06-30 | -4.10 | 1.31 | -5.45 |
2024-03-31 | 9.19 | -37.50 | |
2023-12-31 | -5.15 | 4.54 | -28.12 |
2023-09-30 | -2.54 | 4.10 | -38.03 |
2023-06-30 | -7.19 | 6.14 | -36.65 |
2023-03-31 | -0.84 | 1.36 | -12.62 |
2022-12-31 | -0.17 | 0.27 | -6.37 |
2022-09-30 | -0.78 | 1.22 | -29.40 |
2022-06-30 | -0.72 | 1.13 | -129.10 |
2022-03-31 | -2.02 | 0.51 | -15.52 |
2021-12-31 | -2.13 | 0.49 | -90.65 |
2021-09-30 | -2.33 | 0.48 | 179.70 |
2021-06-30 | -3.03 | 0.46 | 9.95 |
2021-03-31 | -5.50 | 0.46 | -17.58 |
2020-12-31 | -6.62 | 0.45 | -15.76 |
2020-09-30 | -7.43 | 0.44 | -31.29 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah -1.21.
- EBIT (3 tahun) / EV untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah -0.95.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-03-31 | -1.21 | -0.95 |
2024-12-31 | -0.82 | -0.63 |
2024-09-30 | -0.67 | -0.86 |
2024-06-30 | -0.24 | -0.29 |
2024-03-31 | -0.10 | -0.15 |
2023-12-31 | -0.19 | -0.29 |
2023-09-30 | -0.39 | -0.30 |
2023-06-30 | -0.13 | -0.20 |
2023-03-31 | -1.13 | -0.57 |
2022-12-31 | -6.69 | -3.13 |
2022-09-30 | -1.32 | -0.62 |
2022-06-30 | -1.44 | -0.64 |
2022-03-31 | -0.52 | -0.26 |
2021-12-31 | -0.52 | -0.26 |
2021-09-30 | -0.49 | -0.31 |
2021-06-30 | -0.41 | -0.28 |
2021-03-31 | -0.18 | -0.22 |
2020-12-31 | -0.15 | -0.21 |
2020-09-30 | -0.14 | -0.20 |
Efektivitas Manajemen
- roa untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah -0.56.
- roe untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah -0.70.
- roic untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah -1.33.
- croic untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah 0.00.
- ocroic untuk Lunai Bioworks Inc. pada 2025 Mar 31 adalah -0.11.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-03-31 | -0.56 | -0.70 | -1.33 | 0.00 | -0.11 |
2024-12-31 | -1.99 | -2.65 | -1.13 | -0.00 | -0.10 |
2024-09-30 | -0.94 | -1.15 | -0.30 | -0.01 | -0.06 |
2024-06-30 | -0.68 | -0.82 | -0.30 | -0.01 | -0.06 |
2024-03-31 | -0.51 | -0.62 | -0.80 | -0.08 | -0.22 |
2023-12-31 | -0.50 | -0.59 | -0.80 | -0.15 | -0.23 |
2023-09-30 | -1.26 | -1.47 | -0.74 | -0.14 | -0.22 |
2023-06-30 | -0.47 | -0.55 | -0.68 | -0.13 | -0.20 |
2023-03-31 | -0.59 | -0.66 | -1.43 | -0.11 | -0.17 |
2022-12-31 | -0.60 | -0.66 | -1.43 | -0.10 | -0.17 |
2022-09-30 | -0.60 | -0.66 | -1.43 | -0.10 | -0.17 |
2022-06-30 | -0.60 | -0.65 | -1.42 | -0.14 | -0.20 |
2022-03-31 | -0.23 | -0.25 | -0.24 | 0.04 | -0.15 |
2021-12-31 | -0.22 | -0.24 | -0.22 | 0.06 | -0.15 |
2021-09-30 | -0.20 | -0.21 | -0.20 | 0.06 | -0.13 |
2021-06-30 | -0.15 | -0.16 | -0.15 | 0.07 | -0.11 |
2021-03-31 | -0.07 | -0.08 | -0.08 | -0.04 | -0.06 |
2020-12-31 | -0.06 | -0.06 | -0.06 | -0.03 | -0.07 |
2020-09-30 | -0.05 | -0.06 | -0.06 | -0.03 | -0.07 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1527728 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |